SKYE
$0.67
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases.
Recent News
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
Skye Bioscience Inc (SKYE) reports promising weight loss results and strategic R&D collaborations, despite challenges in dosing and delivery.
Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye Bioscience
Halozyme Therapeutics (HALO) shares are in focus after the company entered a non exclusive global collaboration with Skye Bioscience in December 2025 to apply its ENHANZE drug delivery technology to a potential obesity treatment. See our latest analysis for Halozyme Therapeutics. The Skye Bioscience agreement lands at a time when Halozyme’s share price has picked up momentum, with a 15.47% 1 month share price return and 12.16% 3 month share price return. The 1 year total shareholder return of...
Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...
Skye Bioscience Inc (SKYE) reports encouraging phase 2A study outcomes but faces increased R&D expenses and net loss.